Loading...
Most of the action around new antiretrovirals at the 2008 International AIDS Conference centered on second-generation NNRTIs, namely IDX899 and RDEA806. The new NRTI apricitabine also generated some buzz.
IDX899 and RDEA806 have both demonstrated in vitro activity against viruses with common NNRTI mutations, including K103N and Y181C. During the late-breaker session, Carlos Zala described a single-center, phase I, sequential, double-blind, placebo-controlled study of IDX899 at doses of 200 mg, 400 mg, and 800 mg once daily for 7 days [Abstract THAB0402]. The study involved 30 treatment-naive individuals with viral loads ≥5000 copies/mL. For all dose groups, the mean viral-load reduction at day 8 was approximately 1.8 log copies/mL, and the m…